Literature DB >> 22908149

Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa.

Thomas Krahn1, Christie Gilmour, Justin Tilak, Sebastien Fraud, Nicholas Kerr, Calvin Ho-Fung Lau, Keith Poole.   

Abstract

Screening of a transposon insertion mutant library of Pseudomonas aeruginosa for increased susceptibility to paromomycin identified a number of genes whose disruption enhanced susceptibility of this organism to multiple aminoglycosides, including tobramycin, amikacin, and gentamicin. These included genes associated with lipid biosynthesis or metabolism (lptA, faoA), phosphate uptake (pstB), and two-component regulators (amgRS, PA2797-PA2798) and a gene of unknown function (PA0392). Deletion mutants lacking these showed enhanced panaminoglycoside susceptibility that was reversed by the cloned genes, confirming their contribution to intrinsic panaminoglycoside resistance. None of these mutants showed increased aminoglycoside permeation of the cell envelope, indicating that increased susceptibility was not related to enhanced aminoglycoside uptake owing to a reduced envelope barrier function. Several mutants (pstB, faoA, PA0392, amgR) did, however, show increased cytoplasmic membrane depolarization relative to wild type following gentamicin exposure, consistent with the membranes of these mutants being more prone to perturbation, likely by gentamicin-generated mistranslated polypeptides. Mutants lacking any two of these resistance genes in various combinations invariably showed increased aminoglycoside susceptibility relative to single-deletion mutants, confirming their independent contribution to resistance and highlighting the complexity of the intrinsic aminoglycoside resistome in P. aeruginosa. Deletion of these genes also compromised the high-level panaminoglycoside resistance of clinical isolates, emphasizing their important contribution to acquired resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908149      PMCID: PMC3486610          DOI: 10.1128/AAC.01446-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  83 in total

1.  Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Arno Muller; Karine Blanc; Patrick Plésiat; Daniel Talon; Dominique Louis Monnet; Xavier Bertrand
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

2.  Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Kristen N Schurek; Alexandra K Marr; Patrick K Taylor; Irith Wiegand; Lucie Semenec; Bhavjinder K Khaira; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

3.  Shifting patterns of inhaled antibiotic use in cystic fibrosis.

Authors:  Samuel M Moskowitz; Stefanie J Silva; Nicole Mayer-Hamblett; David J Pasta; David R Mink; Jenny A Mabie; Michael W Konstan; Jeffrey S Wagener
Journal:  Pediatr Pulmonol       Date:  2008-09

4.  The Pseudomonas aeruginosa PsrA responds to long-chain fatty acid signals to regulate the fadBA5 beta-oxidation operon.

Authors:  Yun Kang; David T Nguyen; Mike S Son; Tung T Hoang
Journal:  Microbiology (Reading)       Date:  2008-06       Impact factor: 2.777

5.  Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study.

Authors:  Ja-Young Kim; Yeon-Joon Park; Hi Jeong Kwon; Kyungja Han; Moon Won Kang; Gun-Jo Woo
Journal:  J Antimicrob Chemother       Date:  2008-07-07       Impact factor: 5.790

6.  NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.

Authors:  Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

Review 7.  Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  G Taccetti; S Campana; A S Neri; V Boni; F Festini
Journal:  J Chemother       Date:  2008-04       Impact factor: 1.714

8.  Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).

Authors:  Véronique Dubois; Corinne Arpin; Virginie Dupart; Aline Scavelli; Laure Coulange; Catherine André; Isabelle Fischer; Frédéric Grobost; Jean-Philippe Brochet; Isabelle Lagrange; Brigitte Dutilh; Jacqueline Jullin; Patrick Noury; Gilberte Larribet; Claudine Quentin
Journal:  J Antimicrob Chemother       Date:  2008-05-08       Impact factor: 5.790

9.  Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death.

Authors:  Michael A Kohanski; Daniel J Dwyer; Jamey Wierzbowski; Guillaume Cottarel; James J Collins
Journal:  Cell       Date:  2008-11-14       Impact factor: 41.582

10.  Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms.

Authors:  Heidi Mulcahy; Laetitia Charron-Mazenod; Shawn Lewenza
Journal:  PLoS Pathog       Date:  2008-11-21       Impact factor: 6.823

View more
  27 in total

1.  GigA and GigB are Master Regulators of Antibiotic Resistance, Stress Responses, and Virulence in Acinetobacter baumannii.

Authors:  Michael J Gebhardt; Howard A Shuman
Journal:  J Bacteriol       Date:  2017-04-25       Impact factor: 3.490

2.  Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa.

Authors:  Zeinab Hosseinidoust; Nathalie Tufenkji; Theo G M van de Ven
Journal:  Appl Environ Microbiol       Date:  2013-02-22       Impact factor: 4.792

3.  Analysis of the Pseudomonas aeruginosa Aminoglycoside Differential Resistomes Allows Defining Genes Simultaneously Involved in Intrinsic Antibiotic Resistance and Virulence.

Authors:  Fernando Sanz-García; Carolina Alvarez-Ortega; Jorge Olivares-Pacheco; Paula Blanco; José Luis Martínez; Sara Hernando-Amado
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives.

Authors:  Sylvie Garneau-Tsodikova; Kristin J Labby
Journal:  Medchemcomm       Date:  2015-09-21       Impact factor: 3.597

5.  Antibiotic Resistance in Pseudomonas.

Authors:  Pablo Laborda; Sara Hernando-Amado; José Luis Martínez; Fernando Sanz-García
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

6.  Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.

Authors:  Marina Borisova; Jonathan Gisin; Christoph Mayer
Journal:  Microb Drug Resist       Date:  2014-05-12       Impact factor: 3.431

7.  Mutational activation of the AmgRS two-component system in aminoglycoside-resistant Pseudomonas aeruginosa.

Authors:  Calvin Ho-Fung Lau; Sebastien Fraud; Marcus Jones; Scott N Peterson; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

8.  Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.

Authors:  Keith Poole; Christie Gilmour; Maya A Farha; Erin Mullen; Calvin Ho-Fung Lau; Eric D Brown
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.

Authors:  Alaya Mikalauskas; Michael D Parkins; Keith Poole
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

10.  Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004.

Authors:  Shuai Le; Xuesong He; Yinling Tan; Guangtao Huang; Lin Zhang; Renate Lux; Wenyuan Shi; Fuquan Hu
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.